Human Antibody Core

人类抗体核心

基本信息

批准号：
8726079
负责人：
Kenneth Michael Smith
金额：
$ 22.33万
依托单位：
OKLAHOMA MEDICAL RESEARCH FOUNDATION
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/8726079
关键词：
Anthrax Vaccine Absorbed Anthrax Vaccines Anthrax disease Antibodies Antibody Formation Antibody Specificity Antigens B-Lymphocytes Bacillus anthracis Binding Cells Complex Core Facility Enzyme-Linked Immunosorbent Assay Epitopes Flow Cytometry Foundations Funding Genus staphylococcus Goals Histones Human Immune response Immunization Immunoglobulin G Immunoglobulin-Secreting Cells Immunologics Immunology Immunotherapeutic agent In Vitro Individual Infection Inflammation Influenza Influenza A Virus, H1N1 Subtype Length Libraries Medical Research Memory Memory B-Lymphocyte Molecular Monoclonal Antibodies Nucleosomes Oklahoma Organism Patients Peptidoglycan Polysaccharides Process Production Rabies Reagent Recording of previous events Research Research Personnel Sepsis Sorting - Cell Movement Specificity Streptococcus Streptococcus pneumoniae Systemic Lupus Erythematosus Techniques Technology Testing United Kingdom Vaccinated Vaccination Vaccines Vaccinia virus Western Blotting Work anthrax lethal factor anthrax protective factor base human monoclonal antibodies in vivo interest member new technology novel novel diagnostics pandemic disease pathogen research study scale up screening tool volunteer

项目摘要

The Human Antibody Core Facility is based on a technology that was developed at the Oklahoma Medical Research Foundation. The technology facilitates the production of fully human, full-length, antigen-specific monoclonal antibodies. The process can be completed in as little as 28 days post infection or immunization and creates full-length, properly paired antibodies of any desired IgG subclass. As a core facility, we have produced human monoclonals for a variety of purposes including novel diagnostics, passive immunotherapeutics and most importantly, understanding human immune responses to vaccination. We currently have a library of over nine hundred monoclonal antibodies. Known specificities include seasonal and pandemic H1N1, H3N2 and B influenza strains, S. pneumoniae capsular polysaccharide, rabies and vaccinia virus, and anthrax protective antigen (PA). In particular, our antibodies to anthrax protective antigen (PA), derived from an individual vaccinated with Anthrax Vaccine Absorbed (AVA), were carefully characterized, and two antibodies which bound to complex conformational epitopes of PA were shown to be protective against lethal toxin challenge both in vitro and in vivo. Our core facility produced these anti-PA monoclonals with previous funding as a member of the Cooperative Centers for Human Immunology during the last six years.

人类抗体核心设施基于俄克拉荷马州开发的技术医学研究基金会。该技术有助于生产全人、全长、抗原特异性的单克隆抗体。该过程可在感染后 28 天内完成，或者免疫并产生任何所需 IgG 亚类的全长、正确配对的抗体。作为核心设施，我们生产了用于多种目的的人类单克隆抗体，包括新型诊断、被动免疫治疗，最重要的是，了解人类免疫反应疫苗接种。我们目前拥有超过九百种单克隆抗体的库。已知的特殊性包括季节性和大流行性 H1N1、H3N2 和 B 型流感病毒株、肺炎链球菌荚膜多糖、狂犬病和牛痘病毒以及炭疽保护性抗原（PA）。特别是我们的抗体炭疽保护性抗原 (PA)，源自接种炭疽疫苗的个体（AVA），经过仔细表征，两种抗体结合到复杂的构象表位 PA 在体外和体内均显示出对致命毒素攻击的保护作用。我们的核心设施作为合作中心的成员，利用先前的资金生产了这些抗 PA 单克隆抗体过去六年的人类免疫学。